Novartis' panobinostat impresses in myeloma trial
18th December 2013
Novartis has posted promising late-stage data on a new treatment for multiple
myeloma which shows that the drug improves progression-free survival when
combined with two already-marketed drugs.
The compound in question is called panobinostat and top-line results from a
Phase III trial demonstrate that the drug, also known as LBH589, significantly
extended PFS in patients with relapsed or relapsed and refractory MM in
combination with Johnson & Johnson’s Velcade (bortezomib) and dexamethasone,
compared with the latter two drugs alone. Full results from the study will be
presented at an upcoming medical congress and discussed with regulatory
authorities worldwide, Novartis noted.